Orchestra BioMed Holdings' AVIM product received FDA breakthrough device designation, accelerating approval and offering speculative optimism for investors. The firm is pre-revenue with significant ...
Breakthrough Device Designation (“BDD”) applies to an estimated U.S. population of over 7.7 million patients with uncontrolled hypertension and increased cardiovascular risk BDD also encompasses ...
Orchestra BioMed has announced that the FDA has granted Breakthrough Device Designation for its atrioventricular interval modulation (AVIM) therapy, aimed at treating over 7.7 million U.S. patients ...
LONDON--(BUSINESS WIRE)--The global anesthesia gas blenders market is expected to grow by USD 110 million during 2019-2023, according to the latest market research report by Technavio, progressing at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback